The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery. The European Society of Retina ...

In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD, and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed ...

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies. Note: The following transcript has been lightly edited for clarity. Sofia Androudi, MD: ...

María Berrocal, from Drs. Berrocal and Associates in San Juan, Puerto Rico, delivered the Ingrid Kreissig Award Lecture titled "Throwing away wisdom: How we abandon what works." Her presentation ...

At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma. Jean-Francois Korobelnik, MD, ...

Elon van Dijk, an ophthalmologist from the Netherlands working at Leiden University Medical Center and Rotterdam Eye Hospital, delivered a comprehensive presentation on central serous ...

The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress. Marion Munk, a medical retina and uveitis specialist from Switzerland, introduced the ...

The Vit-Buckle Symposium will be a part of the at EURETINA annual meeting in Paris, France again this year. To discuss this symposium, Aleksandra Rachitskaya, MD, FASRS, from Cleveland Clinic Cole Eye ...

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...

Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only FDA-approved treatment for adults with idiopathic macular ...